Genetic tumor adaptation to kinase inhibitors - Lab members

Lab members

  • Ken Olaussen (MCU Univ. Paris-Saclay, HDR)
  • Françoise Farace (Ingénieure IGR, HDR)
  • Benjamin Besse (PU-PH Univ. Paris-Saclay)
  • Christophe Massard (PU-PH Univ. Paris-Saclay)
  • David Planchard (MD IGR)
  • Patrycja Pawlikowska (Ingénieure de recherche IGR)
  • Floriane Brayé (Ingénieure d’études IGR)
  • Marianne Oulhen (Ingénieure d’études IGR)
  • Pauline Tesson (Technicienne IGR)
  • Agathe Aberlenc (Technicienne IGR)
  • Natalia Pinzon (Post-Doctorante IGR)

Genetic tumor adaptation to kinase inhibitors - publications

Major publications

1: Facchinetti F, Hollebecque A, Bahleda R, Loriot Y, Olaussen KA, Massard C, Friboulet L. Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors. Clin Cancer Res. 2019 Oct 4. doi: 10.1158/1078-0432.CCR-19-2035. [Epub ahead of print] Review. PubMed PMID: 31585937.

nv Research Units

The research groups of Gustave Roussy are gathered in 12 research units:

UMR 1287

UMR 1287 - Hematopoietic stem cells and the development of myeloid malignancies

At the apex of the hematopoietic tissue, hematopoietic stem cells (HSCs) self-renew and give rise to all blood cell lineages. The tightly regulated mechanisms involved in normal hematopoiesis include a number of intrinsic factors, such as transcription factors & epigenetic marks, and extrinsic factors such as surrounding cells of the niche and the cytokines they produce.

UMR 9018

UMR 9018 - Metabolic and systemic aspects of oncogenesis for new therapeutic approaches (METSY)

Catherine Brenner

 

 

Head of unit: Dr Catherine Brenner

 

 

UMR 9019

UMR 9019 - Genome Integrity and Cancers

The Genome Integrity and Cancers unit focuses its efforts on understanding the molecular and cellular mechanisms that govern the stability of the genome, one of the major areas of research at the Gustave Roussy Institute.

Etude ONCOVID

Etude ONCOVID

Covid-19 - Epidémiologie du SARS-CoV-2 et mortalité par maladie de Covid-19 chez les patients français porteurs d’un cancer et traités par l'hydroxychloroquine et l'azithromycine.

Pages